1. |
Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev, 2018, 32(19-20): 1267-1284.
|
2. |
Munn DH, Bronte V. Immune suppressive mechanisms in the tumor microenvironment. Curr Opin Immunol, 2016, 39: 1-6.
|
3. |
Johnson DB, Nebhan CA, Moslehi JJ, et al. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol, 2022, 19(4): 254-267.
|
4. |
Naimi A, Mohammed RN, Raji A, et al. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Commun Signal, 2022, 20(1): 44. doi: 10.1186/s12964-022-00854-y.
|
5. |
Yang F, Shay C, Abousaud M, et al. Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States. J Exp Clin Cancer Res, 2023, 42(1): 4. doi: 10.1186/s13046-022-02568-y.
|
6. |
Ramos-Casals M, Brahmer JR, Callahan MK, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers, 2020, 6(1): 38. doi: 10.1038/s41572-020-0160-6.
|
7. |
Wang SJ, Dougan SK, Dougan M. Immune mechanisms of toxicity from checkpoint inhibitors. Trends Cancer, 2023, 9(7): 543-553.
|
8. |
Liu Y, Zheng P. Preserving the CTLA-4 checkpoint for safer and more effective cancer immunotherapy. Trends Pharmacol Sci, 2020, 41(1): 4-12.
|
9. |
Willsmore ZN, Coumbe BGT, Crescioli S, et al. Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: treatment of melanoma and immune mechanisms of action. Eur J Immunol, 2021, 51(3): 544-556.
|
10. |
Jiang Y, Chen M, Nie H, et al. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum Vaccin Immunother, 2019, 15(5): 1111-1122.
|
11. |
Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med, 2015, 13: 211. doi: 10.1186/s12916-015-0455-8.
|
12. |
Sonpavde GP, Grivas P, Lin Y, et al. Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8 730 patients from clinical trials. Future Oncol, 2021, 17(19): 2545-2558.
|
13. |
Guo X, Chen S, Wang X, et al. Immune-related pulmonary toxicities of checkpoint inhibitors in non-small cell lung cancer: diagnosis, mechanism, and treatment strategies. Front Immunol, 2023, 14: 1138483. doi: 10.3389/fimmu.2023.1138483.
|
14. |
Kim ST, Sheshadri A, Shannon V, et al. Distinct immunophenotypes of T cells in bronchoalveolar lavage fluid from leukemia patients with immune checkpoint inhibitors-related pulmonary complications. Front Immunol, 2021, 11: 590494. doi: 10.3389/fimmu.2020.590494.
|
15. |
Franken A, Van Mol P, Vanmassenhove S, et al. Single-cell transcriptomics identifies pathogenic T-helper 17.1 cells and pro-inflammatory monocytes in immune checkpoint inhibitor-related pneumonitis. J Immunother Cancer, 2022, 10(9): e005323. doi: 10.1136/jitc-2022-005323.
|
16. |
Suresh K, Naidoo J, Zhong Q, et al. The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis. J Clin Invest, 2019, 129(10): 4305-4315.
|
17. |
Wang PM, Zhang ZW, Zhang S, et al. Characterization of immunomodulatory factors and cells in bronchoalveolar lavage fluid for immune checkpoint inhibitor-related pneumonitis. J Cancer Res Clin Oncol, 2023, 149(10): 8019-8026.
|
18. |
Wang YN, Lou DF, Li DY, et al. Elevated levels of IL-17A and IL-35 in plasma and bronchoalveolar lavage fluid are associated with checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer. Oncol Lett, 2020, 20(1): 611-622.
|
19. |
Rubio-Infante N, Ramírez-Flores YA, Castillo EC, et al. Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis. Eur J Heart Fail, 2021, 23(10): 1739-1747.
|
20. |
Chen R, Zhou M, Zhu F. Immune checkpoint inhibitors related to cardiotoxicity. J Cardiovasc Dev Dis, 2022, 9(11): 378. doi: 10.3390/jcdd9110378.
|
21. |
Wang D, Bauersachs J, Berliner D. Immune checkpoint inhibitor associated myocarditis and cardiomyopathy: a translational review. Biology (Basel), 2023, 12(3): 472. doi: 10.1097/RHU.0000000000001874.
|
22. |
Zhu H, Galdos FX, Lee D, et al. Identification of pathogenic immune cell subsets associated with checkpoint inhibitor-induced myocarditis. Circulation, 2022, 146(4): 316-335.
|
23. |
Wei SC, Meijers WC, Axelrod ML, et al. A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention. Cancer Discov, 2021, 11(3): 614-625.
|
24. |
Palaskas N, Lopez-Mattei J, Durand JB, et al. Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. J Am Heart Assoc, 2020, 9(2): e013757. doi: 10.1161/JAHA.119.013757.
|
25. |
Rubio-Infante N, Ramírez-Flores YA, Castillo EC, et al. A systematic review of the mechanisms involved in immune checkpoint inhibitors cardiotoxicity and challenges to improve clinical safety. Front Cell Dev Biol, 2022, 10: 851032. doi: 10.3389/fcell.2022.851032.
|
26. |
Taherian M, Chatterjee D, Wang H. Immune checkpoint inhibitor-induced hepatic injury: a clinicopathologic review. J Clin Transl Pathol, 2022, 2(3): 83-90.
|
27. |
Ng KYY, Tan SH, Tan JJE, et al. Impact of immune-related adverse events on efficacy of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma. Liver Cancer, 2021, 11(1): 9-21.
|
28. |
Shojaie L, Ali M, Iorga A, et al. Mechanisms of immune checkpoint inhibitor-mediated liver injury. Acta Pharm Sin B, 2021, 11(12): 3727-3739.
|
29. |
Hercun J, Vincent C, Bilodeau M, et al. Immune-mediated hepatitis during immune checkpoint inhibitor cancer immunotherapy: lessons from autoimmune hepatitis and liver immunology. Front Immunol, 2022, 13: 907591. doi: 10.3389/fimmu.2022.907591.
|
30. |
Siwicki M, Gort-Freitas NA, Messemaker M, et al. Resident Kupffer cells and neutrophils drive liver toxicity in cancer immunotherapy. Sci Immunol, 2021, 6(61): eabi7083. doi: 10.1126/sciimmunol.abi7083.
|
31. |
Oh DY, Cham J, Zhang L, et al. Immune toxicities elicted by CTLA-4 blockade in cancer patients are associated with early diversification of the T-cell repertoire. Cancer Res, 2017, 77(6): 1322-1330.
|
32. |
Dong H, Xue C, Zheng Y, et al. Efficacy and safety of immune checkpoint inhibitors in patients with cancer and hepatitis B or C: a systematic review and meta-analysis. J Oncol, 2023, 2023: 2525903. doi: 10.1155/2023/2525903.
|
33. |
Hagiwara S, Nishida N, Kudo M. Advances in immunotherapy for hepatocellular carcinoma. Cancers (Basel), 2023, 15(7): 2070. doi: 10.3390/cancers15072070.
|
34. |
Papatheodoridis GV, Lekakis V, Voulgaris T, et al. Hepatitis B virus reactivation associated with new classes of immuno-suppressants and immunomodulators: a systematic review, meta-analysis, and expert opinion. J Hepatol, 2022, 77(6): 1670-1689.
|
35. |
Losurdo G, Angelillo D, Favia N, et al. Checkpoint inhibitor-induced colitis: an update. Biomedicines, 2023, 11(5): 1496. doi: 10.3390/biomedicines11051496.
|
36. |
Nielsen DL, Juhl CB, Chen IM, et al. Immune checkpoint inhibitor-induced diarrhea and colitis: incidence and management. a systematic review and meta-analysis. Cancer Treat Rev, 2022, 109: 102440.
|
37. |
Sasson SC, Slevin SM, Cheung VTF, et al. Interferon-gamma-producing CD8+ tissue resident memory T cells are a targetable hallmark of immune checkpoint inhibitor-colitis. Gastroenterology, 2021, 161(4): 1229-1244. e9. doi: 10.1053/j.gastro.2021.06.025.
|
38. |
Chaput N, Lepage P, Coutzac C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol, 2017, 28(6): 1368-1379.
|
39. |
Vétizou M, Pitt JM, Daillère R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science, 2015, 350(6264): 1079-1084.
|
40. |
Sprangers B, Leaf DE, Porta C, et al. Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury. Nat Rev Nephrol, 2022, 18(12): 794-805.
|
41. |
Kanbay M, Copur S, Siriopol D, et al. The association between acute kidney injury and outcomes in cancer patients receiving immune checkpoint inhibitor therapy: a systematic review and meta-analysis. Clin Kidney J, 2022, 16(5): 817-826.
|
42. |
Longhitano E, Muscolino P, Lo Re C, et al. Immune checkpoint inhibitors and the kidney: a focus on diagnosis and management for personalised medicine. Cancers (Basel), 2023, 15(6): 1891. doi: 10.3390/cancers15061891.
|
43. |
Fadel F, El Karoui K, Knebelmann B. Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med, 2009, 361(2): 211-212.
|
44. |
Koda R, Watanabe H, Tsuchida M, et al. Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report. BMC Nephrol, 2018, 19(1): 48. doi: 10.1186/s12882-018-0848-y.
|
45. |
Watanabe T, Yamaguchi Y. Cutaneous manifestations associated with immune checkpoint inhibitors. Front Immunol, 2023, 14: 1071983. doi: 10.3389/fimmu.2023.1071983.
|
46. |
Yamamoto T. Skin manifestation induced by immune checkpoint inhibitors. Clin Cosmet Investig Dermatol, 2022, 15: 829-841.
|
47. |
Freeman-Keller M, Kim Y, Cronin H, et al. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res, 2016, 22(4): 886-894.
|
48. |
Tsiogka A, Bauer JW, Patsatsi A. Bullous pemphigoid associated with anti-programmed cell death protein 1 and anti-programmed cell death ligand 1 therapy: a review of the literature. Acta Derm Venereol, 2021, 101(1): adv00377. doi: 10.2340/00015555-3740.
|
49. |
Shi VJ, Rodic N, Gettinger S, et al. Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy. JAMA Dermatol, 2016, 152(10): 1128-1136.
|
50. |
Muir CA, Tsang VHM, Menzies AM, et al. Immune related adverse events of the thyroid—a narrative review. Front Endocrinol (Lausanne), 2022, 13: 886930. doi: 10.3389/fendo.2022.886930.
|
51. |
Chye A, Allen I, Barnet M, et al. Insights into the host contribution of endocrine associated immune-related adverse events to immune checkpoint inhibition therapy. Front Oncol, 2022, 12: 894015. doi: 10.3389/fonc.2022.894015.
|
52. |
Yasuda Y, Iwama S, Sugiyama D, et al. CD4+ T cells are essential for the development of destructive thyroiditis induced by anti-PD-1 antibody in thyroglobulin-immunized mice. Sci Transl Med, 2021, 13(593): eabb7495. doi: 10.1126/scitranslmed.abb7495.
|
53. |
Iwama S, Kobayashi T, Arima H. Clinical characteristics, management, and potential biomarkers of endocrine dysfunction induced by immune checkpoint inhibitors. Endocrinol Metab (Seoul), 2021, 36(2): 312-321.
|
54. |
Haanen J, Obeid M, Spain L, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol, 2022, 33(12): 1217-1238.
|
55. |
Thompson JA, Schneider BJ, Brahmer J, et al. NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020. J Natl Compr Canc Netw, 2020, 18(3): 230-241.
|
56. |
Verheijden RJ, van Eijs MJM, May AM, et al. Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance. NPJ Precis Oncol, 2023, 7(1): 41. doi: 10.1038/s41698-023-00380-1.
|
57. |
Petrelli F, Signorelli D, Ghidini M, et al. Association of steroids use with survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Cancers (Basel), 2020, 12(3): 546. doi: 10.3390/cancers12030546.
|